CCL17 and pulmonary fibrosis: In addition, as the combination of CCL17 and total POSTN showed excellent performance for predicting non-IPF-ILD progression in the discovery cohort, developing a combination of multiple biomarkers is expected to more accurately determine the complex pathogenesis of pulmonary fibrosis.